tetano
Editor, Senior Moderator
Microbiol Spectr
. 2021 Dec 1;e0056021.
doi: 10.1128/Spectrum.00560-21. Online ahead of print.
Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants
Yoshitomo Morinaga[SUP] 1 [/SUP], Hideki Tani[SUP] 1 2 [/SUP], Yasushi Terasaki[SUP] 3 [/SUP], Satoshi Nomura[SUP] 3 [/SUP], Hitoshi Kawasuji[SUP] 4 [/SUP], Takahisa Shimada[SUP] 1 2 [/SUP], Emiko Igarashi[SUP] 2 [/SUP], Yumiko Saga[SUP] 1 2 [/SUP], Yoshihiro Yoshida[SUP] 1 [/SUP], Rei Yasukochi[SUP] 4 [/SUP], Makito Kaneda[SUP] 4 [/SUP], Yushi Murai[SUP] 4 [/SUP], Akitoshi Ueno[SUP] 4 [/SUP], Yuki Miyajima[SUP] 4 [/SUP], Yasutaka Fukui[SUP] 4 [/SUP], Kentaro Nagaoka[SUP] 4 [/SUP], Chikako Ono[SUP] 5 6 [/SUP], Yoshiharu Matsuura[SUP] 5 6 [/SUP], Takashi Fujimura[SUP] 3 [/SUP], Yoichi Ishida[SUP] 3 [/SUP], Kazunori Oishi[SUP] 7 [/SUP], Yoshihiro Yamamoto[SUP] 4 [/SUP]
Affiliations
Abstract
Serological tests are beneficial for recognizing the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). To identify protective immunity, optimization of the chemiluminescent reduction neutralizing test (CRNT) is critical. Whether commercial antibody tests have comparable accuracy is unknown. Serum samples were obtained from COVID-19 patients (n = 74), SARS-CoV-2 PCR-negative (n = 179), and suspected healthy individuals (n = 229) before SARS-CoV-2 variants had been detected locally. The convalescent phase was defined as the period after day 10 from disease onset or the episode of close contact. The CRNT using pseudotyped viruses displaying the wild-type (WT) spike protein and a commercial anti-receptor-binding domain (RBD) antibody test were assayed. Serology for the B.1.1.7 and B.1.351 variants was also assayed. Both tests concurred for symptomatic COVID-19 patients in the convalescent phase. They clearly differentiated between patients and suspected healthy individuals (sensitivity: 95.8% and 100%, respectively; specificity: 99.1% and 100%, respectively). Anti-RBD antibody test results correlated with neutralizing titers (r = 0.31, 95% confidence interval [CI] 0.22-0.38). Compared with the WT, lower CRNT values were observed for the variants. Of the samples with ≥100 U/mL by the anti-RBD antibody test, 77.8% and 88.9% showed ≥50% neutralization against the B.1.1.7 and the B.1.351 variants, respectively. Exceeding 100 U/mL in the anti-RBD antibody test was associated with neutralization of variants (P < 0.01). The CRNT and commercial anti-RBD antibody test effectively classified convalescent COVID-19 patients. Strong positive results with the anti-RBD antibody test can reflect neutralizing activity against emerging variants. IMPORTANCE This study provides a diagnostic evidence of test validity, which can lead to vaccine efficacy and proof of recovery after COVID-19. It is not easy to know neutralization against SARS-CoV-2 in the clinical laboratory because of technical and biohazard issues. The correlation of the quantitative anti-receptor-binding domain antibody test, which is widely available, with neutralizing test indicates that we can know indirectly the state of acquisition of functional immunity against wild and variant-type viruses in the clinical laboratory.
Keywords: convalescent; high throughput; neutralizing antibodies; receptor-binding domain; seroconversion.
. 2021 Dec 1;e0056021.
doi: 10.1128/Spectrum.00560-21. Online ahead of print.
Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants
Yoshitomo Morinaga[SUP] 1 [/SUP], Hideki Tani[SUP] 1 2 [/SUP], Yasushi Terasaki[SUP] 3 [/SUP], Satoshi Nomura[SUP] 3 [/SUP], Hitoshi Kawasuji[SUP] 4 [/SUP], Takahisa Shimada[SUP] 1 2 [/SUP], Emiko Igarashi[SUP] 2 [/SUP], Yumiko Saga[SUP] 1 2 [/SUP], Yoshihiro Yoshida[SUP] 1 [/SUP], Rei Yasukochi[SUP] 4 [/SUP], Makito Kaneda[SUP] 4 [/SUP], Yushi Murai[SUP] 4 [/SUP], Akitoshi Ueno[SUP] 4 [/SUP], Yuki Miyajima[SUP] 4 [/SUP], Yasutaka Fukui[SUP] 4 [/SUP], Kentaro Nagaoka[SUP] 4 [/SUP], Chikako Ono[SUP] 5 6 [/SUP], Yoshiharu Matsuura[SUP] 5 6 [/SUP], Takashi Fujimura[SUP] 3 [/SUP], Yoichi Ishida[SUP] 3 [/SUP], Kazunori Oishi[SUP] 7 [/SUP], Yoshihiro Yamamoto[SUP] 4 [/SUP]
Affiliations
- PMID: 34851163
- DOI: 10.1128/Spectrum.00560-21
Abstract
Serological tests are beneficial for recognizing the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). To identify protective immunity, optimization of the chemiluminescent reduction neutralizing test (CRNT) is critical. Whether commercial antibody tests have comparable accuracy is unknown. Serum samples were obtained from COVID-19 patients (n = 74), SARS-CoV-2 PCR-negative (n = 179), and suspected healthy individuals (n = 229) before SARS-CoV-2 variants had been detected locally. The convalescent phase was defined as the period after day 10 from disease onset or the episode of close contact. The CRNT using pseudotyped viruses displaying the wild-type (WT) spike protein and a commercial anti-receptor-binding domain (RBD) antibody test were assayed. Serology for the B.1.1.7 and B.1.351 variants was also assayed. Both tests concurred for symptomatic COVID-19 patients in the convalescent phase. They clearly differentiated between patients and suspected healthy individuals (sensitivity: 95.8% and 100%, respectively; specificity: 99.1% and 100%, respectively). Anti-RBD antibody test results correlated with neutralizing titers (r = 0.31, 95% confidence interval [CI] 0.22-0.38). Compared with the WT, lower CRNT values were observed for the variants. Of the samples with ≥100 U/mL by the anti-RBD antibody test, 77.8% and 88.9% showed ≥50% neutralization against the B.1.1.7 and the B.1.351 variants, respectively. Exceeding 100 U/mL in the anti-RBD antibody test was associated with neutralization of variants (P < 0.01). The CRNT and commercial anti-RBD antibody test effectively classified convalescent COVID-19 patients. Strong positive results with the anti-RBD antibody test can reflect neutralizing activity against emerging variants. IMPORTANCE This study provides a diagnostic evidence of test validity, which can lead to vaccine efficacy and proof of recovery after COVID-19. It is not easy to know neutralization against SARS-CoV-2 in the clinical laboratory because of technical and biohazard issues. The correlation of the quantitative anti-receptor-binding domain antibody test, which is widely available, with neutralizing test indicates that we can know indirectly the state of acquisition of functional immunity against wild and variant-type viruses in the clinical laboratory.
Keywords: convalescent; high throughput; neutralizing antibodies; receptor-binding domain; seroconversion.